Genetic products differentially expressed in tumors and use thereof
The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
1. A pharmaceutical composition comprising an antibody conjugated to a therapeutic agent and a pharmaceutically compatible carrier or adjuvant, wherein the antibody is capable of specifically binding to an extracellularly exposed region of a protein or polypeptide, said protein or polypeptide being encoded by a nucleic acid which is selected from the group consisting essentially of:
(a) a nucleic acid which comprises a nucleic acid sequence set forth in SEQ ID NO. 19; and (b) a nucleic acid which hybridizes with the complement to the nucleic acid of (a) under stringent conditions, wherein the stringent conditions are a hybridization temperature of 65° C. in a hybridization buffer containing 3.5×SSC, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin, 2.5 mM NaH 2 PO 4 , 0.5% SDS, and 2 mM EDTA, wherein after hybridization, the membrane to which the DNA has been transferred is washed in 2×SSC at room temperature and then in 1.5×SSC/0.1×SDS at temperatures of up to 68° C.
2. The pharmaceutical composition as claimed in claim 1 , wherein the protein or polypeptide comprises an amino acid sequence set forth in SEQ ID NO:22.
3. The pharmaceutical composition as claimed in claim 1 , wherein the antibody is a monoclonal, chimeric or humanized antibody or a fragment thereof.
4. The pharmaceutical composition as claimed in any of claim 1 , 2 , or 3 , wherein the therapeutic agent is a toxin.
5. The pharmaceutical composition of claim 1 , wherein the extracellularly exposed region of the protein or polypeptide has the amino acid sequence of SEQ ID NO: 81 or SEQ ID NO: 82.
6. A pharmaceutical composition comprising an antibody conjugated to a therapeutic agent and a pharmaceutically compatible carrier or adjuvant, wherein the antibody is capable of specifically binding to a protein or polypeptide, said protein or polypeptide being encoded by a nucleic acid which is selected from the group consisting essentially of:
(a) a nucleic acid which comprises a nucleic acid sequence set forth in SEQ ID NO. 19; and (b) a nucleic acid which hybridizes with the complement to the nucleic acid of (a) under stringent conditions, wherein the stringent conditions are a hybridization temperature of 65° C. in a hybridization buffer containing 3.5×SSC, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin, 2.5 mM NaH 2 PO 4 , 0.5% SDS, and 2 mM EDTA, wherein after hybridization, the membrane to which the DNA has been transferred is washed in 2×SSC at room temperature and then in 1.5×SSC/0.1×SDS at temperatures of up to 68° C.
7. The pharmaceutical composition as claimed in claim 6 , wherein the protein or polypeptide comprises an amino acid sequence set forth in SEQ ID NO:22.
8. The pharmaceutical composition as claimed in claim 6 , wherein the antibody is a monoclonal, chimeric or humanized antibody or a fragment thereof.
9. The pharmaceutical composition as claimed in any of claims 6 - 8 , wherein the therapeutic agent is a toxin.
10. A method of treating a cancer in a patient, comprising:
administering to the patient a pharmaceutical composition comprising an antibody conjugated to a therapeutic agent and a pharmaceutically compatible carrier or adjuvant, wherein the antibody is capable of specifically binding to an extracellularly exposed region of a protein or polypeptide, said protein or polypeptide being encoded by a nucleic acid which is selected from the group consisting essentially of:
(a) a nucleic acid which comprises a nucleic acid sequence set forth in SEQ ID NO. 19; and (b) a nucleic acid which hybridizes with the complement to the nucleic acid of (a) under stringent conditions, wherein the stringent conditions are a hybridization temperature of 65° C. in a hybridization buffer containing 3.5×SSC, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin, 2.5 mM NaH 2 PO 4 , 0.5% SDS, and 2 mM EDTA, wherein after hybridization, the membrane to which the DNA has been transferred is washed in 2×SSC at room temperature and then in 1.5×SSC/0.1×SDS at temperatures of up to 68° C.;
wherein the cancer is characterized by expression or abnormal expression of said protein or polypeptide.
11. The method of claim 10 , wherein the protein or polypeptide comprises an amino acid sequence set forth in SEQ ID NO:22.
12. The method of claim 10 , wherein the antibody is a monoclonal, chimeric or humanized antibody or a fragment thereof.
13. The method of any one of claims 10 - 12 , wherein the therapeutic agent is a toxin.
14. The method of claim 10 , wherein the extracellularly exposed region of the protein or polypeptide has the amino acid sequence of SEQ ID NO: 81 or SEQ ID NO: 82.
15. The method of claim 10 , wherein the cancer is a melanoma, a mammary carcinoma, a prostate carcinoma, a bronchial carcinoma, a ovarian carcinoma, or a cervical carcinoma, each of which is characterized by expression or abnormal expression of the protein or polypeptide.